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Abstract
Amelogenesis imperfecta (AI) describes a heterogeneous group of developmental enamel
defects that typically have Mendelian inheritance. Exome sequencing of 10 families with
recessive hypomaturation AI revealed four novel and one known variants in the matrix
metallopeptidase 20 (MMP20) gene that were predicted to be pathogenic. MMP20 en-
codes a protease that cleaves the developing extracellular enamel matrix and is neces-
sary for normal enamel crystal growth during amelogenesis. New homozygous missense
changes were shared between four families of Pakistani heritage (c.625G>C;
p.(Glu209Gln)) and two of Omani origin (c.710C>A; p.(Ser237Tyr)). In two families of UK
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origin and one from Costa Rica, affected individuals were homozygous for the previously
reported c.954‐2A>T; p.(Ile319Phefs*19) variant. For each of these variants, micro-
satellite haplotypes appeared to exclude a recent founder effect, but elements of hap-
lotype were conserved, suggesting more distant founding ancestors. New compound
heterozygous changes were identified in one family of the European heritage:
c.809_811+12delinsCCAG; p.(?) and c.1122A>C; p.(Gln374His). This report further
elucidates the mutation spectrum of MMP20 and the probable impact on protein func-
tion, confirms a consistent hypomaturation phenotype and shows that mutations in
MMP20 are a common cause of autosomal recessive AI in some communities.
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1 | INTRODUCTION
The hardness of dental enamel is remarkable and is a result of its
high mineral and low protein content (C. E. Smith, 1998). The process
of enamel formation, amelogenesis, begins with the production of a
secreted soft enamel protein matrix, which is then transformed into a
mature, organized structure of rod and interrod enamel crystallites
almost devoid of protein. Crucial to this transformation process is
the secretory stage enamel protease, matrix metallopeptidase 20
(MMP20) [NM_004771.4, ENST00000260228.2] (MIM #604629).
MMP20 is a zinc‐dependent endopeptidase that is secreted in
trace amounts during the secretory and transition stages of amelo-
genesis by ameloblasts (Llano et al., 1997; Seymen et al., 2015). Once
activated, it selectively cleaves the secreted enamel proteins: ame-
logenin, enamelin, and ameloblastin into several products with dis-
tinct functional roles (Simmer & Hu, 2002). MMP20 is also thought
to facilitate ameloblast movement during secretion, through cell–cell
communication, and may influence ameloblast gene expression
(Guan & Bartlett, 2013). These activities create a newly voided space
within which enamel crystallites are able to grow in width and
thickness, and finally, to interlock (Bartlett, 2013). If they are not
removed, the enamel proteins occupy the enamel volume and restrict
the growth of the enamel crystallites. This produces immature
enamel that fails prematurely due to its inability to resist the
mechanical stress resulting from biting and chewing.
Mutations inMMP20 and 19 other genes have been shown to cause
nonsyndromic amelogenesis imperfecta (AI) with autosomal dominant,
autosomal recessive, or X‐linked inheritance (J. W. Kim et al., 2019; C. E.
L. Smith et al., 2017, 2020; and http://dna2.leeds.ac.uk/LOVD/genes),
while perhaps as many again have been implicated in syndromic AI
(Dubail et al., 2018; Wright et al., 2015). Some of these genes encode
proteins processed by MMP20, such as the enamel matrix proteins
AMELX (MIM #300391), AMBN (MIM #610259), and ENAM (MIM
#606585). Other genes implicated in AI include the second enamel ma-
trix protease, KLK4 (MIM #603767), and cell adhesion proteins, such as
LAMA3 (MIM #600805), LAMB3 (MIM #150310), and COL17A1 (MIM
#113811). AI, therefore, describes a heterogeneous group of conditions
characterized by inherited enamel defects in both dentitions. It can
present as a hypoplastic phenotype, where a deficit in secretion results in
the formation of a reduced volume of mineralized enamel, or as hypo-
mineralized AI, whereby a failure in maturation results in the enamel of
full thickness but which is soft or brittle and fails prematurely (Gadhia
et al., 2012). Hypomineralized AI can be further subclassified as hypo-
maturation, caused by incomplete removal of protein from the devel-
oping enamel, or hypocalcification, caused by insufficient transport of
calcium ions into the forming enamel (Smith et al., 2017), though these
phenotypes often overlap. Mutations in MMP20 cause autosomal re-
cessive hypomaturation AI. Fourteen pathogenic variants have been re-
ported to date (Table S1), most of which are located in the catalytic
domain of MMP20 and are thought to affect the stability and function-
ality of the protein structure.
This study describes the identification of pathogenic MMP20 var-
iants in 10 families segregating autosomal recessive hypomaturation AI,
providing additional insights into the spectrum ofMMP20 mutations and
associated phenotype. Four novel variants are reported, two of which are
relatively common founder mutations in specific populations. Ad-
ditionally, we perform molecular dynamics (MD) simulations of variants
in the catalytic domain of MMP20 to examine the predicted effect that
these changes have on the protein. This study increases the total re-
ported pathogenic MMP20 variants to 17, suggests that defects in
MMP20 are a more common cause of AI than was previously reported
and enriches our understanding of the effects that mutations in the
catalytic domain of MMP20 can have on its functionality.
2 | MATERIALS AND METHODS
2.1 | Patients
Individuals from each of the 10 families were recruited following in-
formed consent in accordance with the principles outlined in the De-
claration of Helsinki, with local ethical approval (REC 13/YH/0028).
These 10 families are part of a larger AI cohort presenting with a variety
of AI phenotypes. A diagnosis of AI was made by a dentist after clinical
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examination, based on the physical appearance of the dentition, and was
confirmed by dental X‐ray. Genomic DNA was obtained via venous blood
samples, using conventional extraction techniques, or from saliva using
Oragene® DNA Sample Collection kits (DNA Genotek) and extracted
according to the manufacturer's instructions.
2.2 | Whole‐exome sequencing (WES) and analysis
Three micrograms of genomic DNA from a single individual from
each family (marked with an arrow on the pedigrees shown in
Figure 1) were subjected to WES and analyzed as described pre-
viously (C. E. L. Smith et al., 2019). Variants present in the
dbSNP150 database of NCBI or the Genome Aggregation Data-
base (gnomAD; http://gnomad.broadinstitute.org) with a minor
allele frequency ≥1% were excluded. The potential pathogenic
effect of the variants was predicted using Combined Annotation‐
Dependent Depletion (CADD v1.3; https://cadd.gs.washington.
edu) (Rentzsch et al., 2019), the Sorting Intolerant From Tolerant
algorithm (SIFT; Sim et al., 2012), Protein Variation Effect Analy-
zer(PROVEAN; Choi et al., 2012), and MutPred2 (http://mutpred.
mutdb.org/index.html). The potential effect on splicing for each
F IGURE 1 Pedigrees of the 10 families recruited for this study. The genotypes determined from the microsatellite markers are presented
beneath each individual examined. Families 1, 2, and 3 carry the c.954‐2A>T variant; Families 4, 5, 6, and 7 carry the c.625G>C variant;
Families 8 and 9 carry the c.710C>A variant; and Family 10 has the c.809_811+12delinsCCAG and c.1122A>C variants. The common
haplotypes are presented in the same color and the haplotypes without a pathogenic variant are colored gray. The markers are presented in the
order: 11cen, D11S940, D11S1339, MMP20, D11S4108, D11S4159, D11S4161, 11qter. The recruited family members are marked with
an asterisk and the proband in each family is indicated with a black arrow
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intronic variant was predicted by the Human Splicing Finder v3.1
(http://umd.be/HSF3/HSF.shtml).
2.3 | Polymerase chain reaction (PCR) and Sanger
sequencing
Mutations were confirmed and segregation was performed for all
available family members, marked with (*) on each pedigree of
Figure 1. Primer sequences can be found in Table S2. Sanger
sequencing was performed using the BigDye Terminator v3.1 kit
(Life Technologies) according to the manufacturer's instructions and
resolved on an ABI3130xl sequencer (Life Technologies). Results
were analyzed using SeqScape v2.5 (Life Technologies).
2.4 | Microsatellite analysis
Primer sequences for markers were obtained from the UCSC gen-
ome browser and standard HEX‐tagged primers (Sigma‐Aldrich;
Table S2) were used to assess the flanking haplotypes of MMP20.
The analysis was performed as described previously (Nikolopoulos
et al., 2020).
2.5 | Protein structure analysis
The tertiary structure of MMP20 has been determined in atomistic
detail by nuclear magnetic resonance (NMR) (PDB: 2JSD) (Arendt
et al., 2007), which provides the starting structure for MD simula-
tions. Amino acid substitutions were made in the wild type (WT)
structure using the Chimera visualization tool (Pettersen et al.,
2004). MD simulations were performed using AMBER18 (Case et al.,
2018). Protocols used to perform the MD simulations are in the
Supporting Information Methods. Rhapsody was used for in silico
saturation mutagenesis analysis (Ponzoni et al., 2020) and the pre-
diction of the changes in solvent accessibility, residue occlusion, and
free energy (ΔΔG) of the mutated proteins was performed with
Site‐Directed Mutator (SDM) (Pandurangan et al., 2017).
3 | RESULTS
Ten unrelated families presenting with features consistent with au-
tosomal recessive hypomaturation AI, in the absence of any cose-
gregating disease, were recruited for the study (Figures 1 and 2).
Genomic DNA from affected members of each family was subjected
to exome sequencing. Detailed coverage statistics can be found in
F IGURE 2 Clinical images for nine probands at different chronological ages, illustrating the spectrum of variations that can be observed
within the overall, typical features of hypomaturation amelogenesis imperfecta that have been subjected to different post‐eruptive
environments. (a–c) Families 1–3, who all have European heritage and share the same homozygous MMP20 c.954‐2A>T; p.(Ile319Phefs*19)
variant. (d–g) Families 4–7, who all have Pakistani heritage and share the same homozygous MMP20 c.625G>C; p.(Glu209Gln) variant. (h)
Family 9 who, along with Family 8 (no clinical images available), has Omani heritage, and both have the same homozygous MMP20 c.710C>A;
p.(Ser237Tyr) variant. (i) Family 10, of European heritage, which was found to segregate the compound heterozygous MMP20
c.809_811+12delinsCCAG; p.(?) and c.1122A>C; p.(Gln374His) variants
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Table S3. Samples were sequenced in different batches over a period
of some years, with considerable variation in coverage between
batches. Variant files were filtered to select rare variants with high
predicted pathogenicity, then variants in known AI‐causing genes
were highlighted. This revealed biallelic mutations in MMP20
(Table S4) in each family. The position of these variants in the gene is
shown in Figure 3, along with representative electropherograms for
each novel variant. PCR and Sanger sequencing confirmed the
variants segregated with AI in all available family members.
In Families 1, 2, and 3, a homozygous frameshift variant
(NM_004771: c.954‐2A>T, NP_004762: p.(Ile319Phefs*19)) was
identified in intron 6. This has been published previously as a cause
of autosomal recessive hypomaturation AI and is expected to lead to
retention of the sixth intron (J. W. Kim et al., 2005). To confirm this
hypothesis, we attempted to perform reverse‐anscriptase PCR of the
MMP20 transcript on control blood complementary DNA (cDNA).
However, no amplification was achieved, suggesting that the level of
MMP20 expression in blood is below the threshold for detection.
A novel homozygous missense mutation, c.625G>C,
p.(Glu209Gln), was identified in exon 4 as the cause of disease in
Families 4, 5, 6, and 7. This is known variant rs199788797, which has
not previously been associated with a disease phenotype. In the
gnomAD database, this variant has a frequency of 0.000457 in the
South Asian population but is absent from all other reported popu-
lations. E209 is fully conserved in the mammalian clade, as shown in
Figure S1, using the sequences listed in Table S5. Additionally, the
mutation is predicted to be damaging (Table S6).
In Families 8 and 9, a novel homozygous missense mutation,
c.710C>A, p.(Ser237Tyr) was identified in exon 5. This variant is
absent from databases, is evolutionarily conserved in all the mam-
malian species analyzed (Figure S1) and is predicted to be damaging
by all algorithms used (Table S6).
The affected individual in Family 10 was found to be a com-
pound heterozygote for a novel missense mutation c.1122A>C,
p.(Gln374His) in exon 8 and a novel deletion–insertion (delins) var-
iant: c.809_811+12delinsCCAG, p(?), spanning the splice donor site
of intron 5. Both are absent from variant databases. Variant
p.(Gln374His) is predicted to be damaging (Table S6), and Q374 is
conserved in the mammalian clade (Figure S1). Interestingly, mouse
Mmp20 has a histidine in the equivalent position. This presumably
does not have a detrimental effect on the function of the mouse
protein, perhaps due to other changes of the mouse gene that bal-
ance the protein or reflecting differences in enamel development and
function between mouse teeth, which grow throughout life, and
human teeth which do not. Nevertheless, mutation prediction soft-
ware does classify this variant as pathogenic; it is absent from the
gnomAD database, and when paired with a second MMP20 variant it
has given rise to a hypomaturation phenotype consistent with bial-
lelic MMP20 disease. The delins variant is predicted by Human
Splicing Finder to disrupt the intron 5 splice donor site, possibly
leading to retention of the fifth intron (Figure S2).
The families that share variants (Families 1, 2, and 3 with
c.954‐2A>T, Families 4–7 with c.625G>C, and Families 8 and 9 with
c.710C>A) also originate from the same ethnic backgrounds. To
determine whether these families share common founder haplotypes
at theMMP20 locus, we genotyped five microsatellite markers across
a 1.5 cM/3Mb region of chromosome 11q22 in each family, in the
order: 11cen, D11S940, D11S1339, MMP20, D11S4108, D11S4159,
D11S4161, 11qter. The haplotype analysis is shown in Figure 1.
In Omani families 8 and 9, carrying the c.710C>A variant, hap-
lotyping suggests they are closely related. However, the picture is
more complex in the remaining two family groups. Families 1–3 (the
first from Costa Rica, the remaining two from the United Kingdom)
carry the previously published c.954‐2A>T variant. The proband in
F IGURE 3 (a) MMP20 gene diagram. The positions of all known mutations are marked on the gene with a vertical bar, while novel variants
are highlighted in red. (b) Representation of the protein domains with all known mutations marked with vertical bars, as in (a). The zinc‐
dependent peptidase domain is the catalytic domain of the protein, where most pathogenic variants have been found. (c–f) A representative
electropherogram of each of the novel variants found in this study, (c) c.625G>C variant and wild type (WT), (d) c.710C>A variant and WT,
(e) c.809_811+12delinsCCAG variant and WT, (f) c.1122A>C variant and WT
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Family 2 is homozygous for a haplotype also seen in Family 3, but
the second haplotype in Family 3 has proximal recombination. Family
1 could share the recombinant haplotype observed in Family 3
together with an unrelated haplotype, but without phase informa-
tion this cannot be confirmed. Interestingly, all three families are
homozygous for D11S4108 100 kb from MMP20. Families 4–7, of
UK–Pakistani origin, carry the c.625G>C variant. The proband in
Family 6 is homozygous for the same haplotype segregating in Family
7. However, a second haplotype with distal recombination is seen in
the second affected sibling in Family 6, suggesting the affected
(unsampled) father carries both haplotypes. Family 5 is homozygous
for a third haplotype, again identical at the proximal end to that in
Family 7 but recombinant at the distal end. In contrast, Family 4 is
homozygous for a fourth haplotype identical to the Family 7 haplo-
type at the distal end but proximally recombinant. Again, all four
families are homozygous for the immediately adjacent marker
D11S4108.
The catalytic center of MMP20 is a 160‐residue domain con-
taining the zinc‐dependent peptidase active site. It contains one
catalytic and one structural zinc ion; the structures modeled here
additionally contain two calcium ions, which are also structural. We
assessed how missense variants affect the protein function by per-
forming MD simulations of the relevant mutated proteins. In addi-
tion, to demonstrate the key role of metal ions in maintaining
MMP20 structure, we performed MD simulations in which the metal
ions were removed. We compared the protein structures and dy-
namics observed for the WT with metal ions present, with those
obtained for p.(Glu209Gln) and p.(Ser237Tyr) from this study
(see Figure 4a) and p.(Thr130Ile) and p.(Leu189Pro) from the lit-
erature (Figure 4b); and also with results of the WT in the absence of
metal ions. Figure 4c shows the root mean squared deviation (RMSD)
of each of the simulations from their starting structures. The
averages calculated for the last 300 ns of each repeat are in Table S7,
and the repeats for the entire 900‐ns simulation are shown sepa-
rately in Figure S3. The calculated RMSD values are continuously
adjusted and recalculated during the 900 ns of the simulation. As
such, the final 300 ns, during which the plots have stabilized, are
selected as the representative RMSD values for each simulation, and
so the average values presented in Table S7 are used for the com-
parison among the variants. An increase in RMSD relative to the WT,
implying decreased protein stability, was observed for all variants,
apart from p.(Thr130Ile). We also analyzed the changes in three key
interatomic interactions between the WT and the variants, atomic
fluctuations (Figure S4a), hydrogen bonding interactions (Table S8),
and salt bridges (Table S9), to provide insight into why these parti-
cular variants cause functionally deleterious changes in protein
structure. The most significant structural distortions were observed
in the simulations performed in the absence of structural zinc and
calcium ions (see Figure S4b,c).
In silico saturation mutagenesis of the MMP20 active site per-
formed by Rhapsody shows that there are regions of the protein that
are significantly more likely to cause a pathogenic effect when the
residues located there are altered (Figure S5). These regions largely
correlate with the sites of the known and novel variants and have an
increased PolyPhen‐2 score (Figure S5). The Rhapsody analysis was
limited to the catalytic domain of MMP20 because it relies on the
availability of a tertiary structure. The results of the SDM analysis
are presented in Table S10, showing the changes of free energy,
residue occlusion, and solvent accessibility for the WT and each
mutant, respectively.
4 | DISCUSSION
Exome sequencing in a cohort of nonsyndromic AI families revealed
biallelic MMP20 variants in 10 autosomal recessive families. MMP20
is a protease that plays an essential role during the secretory and
early transition stages of amelogenesis. Defects in MMP20 cause AI
in both humans and mice, due to a failure to process, degrade, and
remove proteins from the extracellular matrix scaffold upon which
the developing dental enamel is formed. The hypomaturation phe-
notype observed in these families fits with this hypothesis, with the
dental enamel being of normal volume but characterized by a loss of
translucency, discoloration, and premature enamel loss. Post‐
eruptive changes probably determine the pattern of premature en-
amel failure. The phenotypes observed in the families presented are
consistent with those described in previous reports of AI due to
MMP20 variants.
The variant identified in Families 1–3, (c.954‐2A>T), has been
reported previously (Gasse et al., 2017; J. W. Kim et al., 2005; Prasad
et al., 2015; Wright et al., 2011), but it has not been possible to
confirm the effect on splicing experimentally since MMP20 is not
expressed in blood. The prediction that the mutation most likely
results in the loss of exon 7 from the MMP20 transcript (J. W. Kim
et al., 2005), therefore, remains speculative. If confirmed, this would
break the reading frame and lead to an abnormal transcript, which
would be expected to be subject to nonsense‐mediated decay.
MMP20 cDNA cannot be obtained from the blood due to un-
detectable expression levels; however, it could possibly be obtained
from tissues, such as tonsil or appendix, as expression has been de-
tected there and these are routinely removed through routine sur-
gery. However, altered splicing in these tissues would only suggest
that splicing is altered in ameloblasts, instead CRISPR–Cas9 editing
of this gene within ameloblast cell lines might be a better model to
determine whether splicing is affected.
The missense variant identified in Families 4–7, p.(Glu209Gln), is
novel and replaces a negatively charged glutamic acid residue with
neutral glutamine. E209 is a coordinating ligand for calcium ion
binding and is, therefore, critical to the function of MMP20 (Andreini
et al., 2004; Arendt et al., 2007; Yamakoshi et al., 2013). Replace-
ment with glutamine decreases protein stability relative to WT in the
MD simulations (see Table S7). Inspection of the WT atomistic
structure shows that Ε209 has a pair of carboxylate oxygen atoms
oriented toward the nearby Ca2+ ion. In E209, the average distance is
<4 Å for both MD repeats (Table S9). However, the mutant Q209
only has one oxygen; in one of the two duplicate MD trajectories, the
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interaction between this amide oxygen and Ca2+ remains strong (an
interatomic distance of 2.5 Å) but in the other it is completely dis-
rupted (interatomic distance of 6.9 Å), allowing it to form non‐native
hydrogen bonds with other residues (see Table S8).
The novel missense variant identified in Families 8 and 9 replaces
a small serine residue with a larger aromatic tyrosine, p.(Ser237Tyr) in
a highly conserved part of the catalytic domain of MMP20. Corre-
spondingly, the SDM analysis identifies an increase in the folding free
energy of the protein relative to the WT (Table S10), implying that the
variant is less stable. Moreover, in the MD simulations, the larger and
more hydrophobic Y237 results in an increased RMSD (2.35 Å) re-
lative to the WT (1.55 Å). In these trajectories, the main backbone
hydrogen bond formed by S237 (with M244) is also formed by Y237.
However, the number of side‐chain hydrogen bonds is reduced in
Y237 compared with S237 (see Table S8) because the corresponding
tyrosine oxygen protrudes too far into the solvent to participate in
interatomic interactions within the protein.
In Family 10, the delins variant disrupts the intron 5ʹ splice
donor site and is therefore again likely to lead to a transcript that is
subject to nonsense‐mediated decay. The novel c.1122A>C,
p.(Gln374His) variant changes a hydrophilic glutamine residue for a
hydrophobic histidine in the C‐terminal hemopexin‐like domain, as
shown in Figure 3a, disrupting the folding of the protein and
potentially leading to a loss of function.
F IGURE 4 The tertiary structure of the catalytic domain of MMP20, based on the PDB: 2JSD nuclear magnetic resonance model. (a) The
wild‐type (WT) protein structure with the two novel variants, c.625G>C; p.(Glu209Gln) of Families 4–7 and c.710C>A; p.(Ser237Tyr) of
Families 8 and 9, of the active site are presented in the inlays. (b) The WT protein structure with the inlays showing two of the known variants
of the active site of MMP20, c.389C>T; p.(Thr130Ile), and c.566T>C; p.(Leu189Pro). (c) The root mean square deviation (RMSD) of each
modeled variant during molecular dynamics simulations of 900 ns. An increase of RMSD value corresponds to a loss of stability, with the WT
MMP20 structure being the most stable and the MMP20 structure in the absence of structural zinc and calcium ions being the least stable
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Microsatellites were used to determine whether the variants
shared in each of the three family groups were founder alleles,
implying these families are related rather than that these sites are
mutation hotspots. Family 1 is from Costa Rica, the population of
which is largely of mixed European and indigenous American
descent. Families 2 and 3 are Caucasian European families from
the United Kingdom. The c.954‐2A>T variant has been reported
previously in at least six families from France (Gasse et al., 2017;
Prasad et al., 2015) and one from the United States (J. W. Kim
et al., 2005). Ethnicity is given as Caucasian by Prasad and
co‐workers but is not given in the remaining reports. Our haplo-
type analysis shows that this variant is present on three different
chromosomal backgrounds, but elements of the haplotype, in
particular the genotype of D11S4108 100 kb from MMP20, appear
conserved between families. This suggests they may be related but
through a distant common ancestor. The picture is similar for
Families 4, 5, 6, and 7, UK families of Pakistani origin. In contrast,
Families 8 and 9 from Oman share an identical haplotype across
the region tested. These findings, therefore, suggest that MMP20
c.710C>A represents a relatively recent founder mutation in the
Omani population, while c.954‐2A>T and c.625G>C result from
older founder mutations in the Caucasian European and Pakistani
populations.
In addition to the novel p.(Glu209Gln) and p.(Ser237Tyr) var-
iants, we also performed MD for known variants p.(Leu189Pro) and
p.(Thr130Ile) to see if the simulations could provide equivalent
structural insight into the loss of function. Other variants within the
active site of MMP20 that change the ability of zinc ions to form
coordination bonds were not modeled because this will either lead to
substantial structural distortion (as seen with MD in the absence of
calcium or zinc ions), or destabilize the key zinc metal center
essential for catalysis.
For p.(Leu189Pro), while there is only a modest increase in
RMSD relative to the WT, simulation of the behavior of the bound
ligand in the WT and variant shows that replacing bulky lysine with
more compact proline changes the shape of the active site. This leads
to substantial structural rearrangement of the ligand, which is likely
to affect substrate recognition and catalytic activity of the protease
against natural substrates.
The only pathogenic missense variant modeled that did not show
a significantly larger RMSD than the WT was p.(Thr130Ile). While
minor changes in hydrogen bonding interactions were detected
(Table S8), no substantial changes in overall protein structure or
perturbations to interatomic interactions with the ligand or metal
ions were observed. Consequently, our MD simulations do not pro-
vide a structural mechanism for why this variant should be patho-
genic. However, p.(Thr130Ile) is located at the edge of the catalytic
domain, close to regions of the protein that are absent from the
available structure and which, therefore, do not feature in these
simulations.
The 14 MMP20 variants previously reported to cause AI are
shown in Figure 3, together with those newly described herein,
indicating their location in the gene and protein. Previously
reported pathogenic variants consisted of seven missense
variants, two premature stop codons, two frameshifts, and two
putative splice variants. Here, we report a further three missense
and one splice variants, consistent with and extending the spec-
trum of mutations in MMP20 causing autosomal recessive AI. The
three splice variants have not been verified beyond in silico
prediction and therefore remain likely but unproven. These 17
variants, and in particular, the missense variants, cluster
primarily in or near to the zinc‐dependent peptidase domain
(Figure 3). Our analyses suggest that pathogenic mutations in this
domain alter protein stability, while others (Y. J. Kim et al., 2017)
have shown that variants in the catalytic domain can lead to a
reduction or complete loss of enzymatic function. The combina-
tion of recessive inheritance, missense variants that reduce
or abolish function, and the lack of significant difference between
phenotypes associated with missense and nonsense variants,
all point to a loss‐of‐function phenotype, where lack of
functional MMP20 gives rise to a consistent hypomaturation AI
phenotype.
In summary, we have identified 10 families segregating AI due
to four novel and one known mutations in MMP20, and reviewed
previously reported mutations, raising the total number of
AI‐causing MMP20 variants to 18. This expands the spectrum of
MMP20 variants implicated in AI and confirms the association with
a hypomaturation phenotype. Haplotype analysis suggests that
the c.710C>A, p.(Ser237Tyr); c.625G>C, p.(Glu209Gln); and c.954‐
2A>T, p.(Ile319Phefs*19) variants may be relatively common
founder mutations in the Omani, Pakistani, and Caucasian popu-
lations, respectively. Biochemical modeling and MD analyses show
that missense mutations in the catalytic domain alter protein
stability, suggesting that this form of AI is the result of the loss‐of‐
function of MMP20.
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